Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 1.00 |
| ▸ | MAOB | P27338 | 12/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623853 | 1.00 | MAOA (1.00) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Water SCHEMBL2640298 | 0.99 | MAOA (0.97) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Hydrochloric Acid SCHEMBL2640267 | 0.99 | MAOA (0.97) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Hydrochloric Acid SCHEMBL2640254 | 0.97 | MAOA (0.95) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Oxalic Acid SCHEMBL27852318 | 0.94 | MAOA (0.88) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Oxalic Acid SCHEMBL2640532 | 0.94 | MAOA (0.88) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Phosphonic Acid SCHEMBL27852074 | 0.93 | MAOA (0.86) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Phosphoric Acid SCHEMBL2640263 | 0.93 | MAOA (0.86) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Fumaric Acid SCHEMBL2640253 | 0.91 | MAOA (0.83) | MAOAMAOBCYP11B1CYP11B2NCOA3 | |
| Fumaric Acid SCHEMBL27852077 | 0.91 | MAOA (0.83) | MAOAMAOBCYP11B1CYP11B2NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091227-A1 | Use Of 2-Phenyl-6-(1H-Imidazol-1-YL) Quinazoline For Treating Neurodegenerative Diseases, Preferably Alzheimer's Disease | Rottapharm Biotech Srl (IT) | 2024-03-21 | — | — | US | claimed |
| EP-4065123-B1 | USE OF 2-PHENYL-6-(1H-IMIDAZOL-1-YL) QUINAZOLINE FOR THE PREVENTION OF ABUSE AND OF SIDE EFFECTS OF AT LEAST ONE OPIOID | Rottapharm Biotech Srl (IT) | 2024-01-03 | — | — | EP | claimed |
| US-20230000868-A1 | USE OF 2-PHENYL-6-(1H-IMIDAZOL-1-YL) QUINAZOLINE FOR THE PREVENTION OF ABUSE AND OF SIDE EFFECTS OF AT LEAST ONE OPIOID | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-01-05 | — | — | US | claimed |
| EP-4065123-A1 | USE OF 2-PHENYL-6-(1H-IMIDAZOL-1-YL) QUINAZOLINE FOR THE PREVENTION OF ABUSE AND OF SIDE EFFECTS OF AT LEAST ONE OPIOID | Rottapharm Biotech S.r.l. (IT) | 2022-10-05 | — | — | EP | claimed |
| EP-3965769-B1 | USE OF 2-PHENYL-6-(1H-IMIDAZOL-1-YL)QUINAZOLINE FOR TREATING NEURODEGENERATIVE DISEASES, PREFERABLY ALZHEIMER'S DISEASE | Rottapharm Biotech Srl (IT) | 2022-09-07 | — | — | EP | claimed |
| US-20220257598-A1 | Use of 2-Phenyl-6-(1H-Imidazol-1-YL) Quinazoline for Treating Neurodegenerative Diseases, Preferably Alzheimer's Disease | ROTTAPHARM BIOTECH S.R.L. (IT) | 2022-08-18 | — | — | US | claimed |
| EP-3965769-A1 | USE OF 2-PHENYL-6-(1H-IMIDAZOL-1-YL)QUINAZOLINE FOR TREATING NEURODEGENERATIVE DISEASES, PREFERABLY ALZHEIMER'S DISEASE | Rottapharm Biotech S.r.l. (IT) | 2022-03-16 | — | — | EP | claimed |
| CN-113811304-A | Use of 2-phenyl-6- (1H-imidazol-1-yl) quinazoline for the treatment of neurodegenerative diseases, preferably Alzheimer's disease | 罗达制药生物技术有限责任公司 | 2021-12-17 | — | — | CN | claimed |
| WO-2021104639-A1 | USE OF 2-PHENYL-6-(1H-IMIDAZOL-1-YL) QUINAZOLINE FOR THE PREVENTION OF ABUSE AND OF SIDE EFFECTS OF AT LEAST ONE OPIOID | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-06-03 | — | — | WO | claimed |
| WO-2021105414-A1 | USE OF 2-PHENYL-6-(1H-IMIDAZOL-1-YL) QUINAZOLINE FOR THE PREVENTION OF ABUSE AND OF SIDE EFFECTS OF AT LEAST ONE OPIOID | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-06-03 | — | — | WO | claimed |
| WO-2020229329-A1 | USE OF 2-PHENYL-6-(1H-IMIDAZOL-1-YL)QUINAZOLINE FOR TREATING NEURODEGENERATIVE DISEASES, PREFERABLY ALZHEIMER'S DISEASE | ROTTAPHARM BIOTECH S.R.L. (IT) | 2020-11-19 | — | — | WO | claimed |
| EP-3735974-A1 | USE OF 2-PHENYL-6-(1H-IMIDAZOL-1-YL)QUINAZOLINE FOR TREATING NEURODEGENERATIVE DISEASES, PREFERABLY ALZHEIMER'S DISEASE | Rottapharm Biotech S.r.l. (IT) | 2020-11-11 | — | — | EP | claimed |
| EP-2438058-B1 | CRYSTALLINE FORMS OF 6-(1H-IMIDAZOL-1-YL)-2-PHENYLQUINAZOLINE | Rottapharm Biotech Srl (IT) | 2018-04-11 | — | — | EP | claimed |
| US-9174966-B2 | Crystalline forms of 6-(1H-imidazol-1-yl)-2-phenylquinazoline | ROTTAPHARM S.P.A. (IT) | 2015-11-03 | — | — | US | claimed |
| US-20120142713-A1 | CRYSTALLINE FORMS OF 6-(1H-IMIDAZOL-1-YL)-2-PHENYLQUINAZOLINE | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-06-07 | — | — | US | claimed |
| CN-102459237-A | Crystalline forms of 6- ( 1h- imidazol- 1-yl) -2-phenylquinazoline and salts thereof | ROTTAPHARM SPA | 2012-05-16 | — | — | CN | claimed |
| EP-2438058-A2 | CRYSTALLINE FORMS OF 6- ( 1H- IMIDAZOL- 1-YL) -2-PHENYLQUINAZOLINE AND SALTS THEREOF | Rottapharm S.p.A. (IT) | 2012-04-11 | — | — | EP | claimed |
| WO-2010140139-A2 | CRYSTALLINE FORMS OF 6- ( 1H- IMIDAZOL- 1-YL) -2-PHENYLQUINAZOLINE AND SALTS THEREOF | ROTTAPHARM S.P.A. (IT) | 2010-12-09 | — | — | WO | claimed |
| EP-4714435-A2 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2008014822-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A. (IT) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142713-A1 | CRYSTALLINE FORMS OF 6-(1H-IMIDAZOL-1-YL)-2-PHENYLQUINAZOLINE | ABCG2, CYP3A5, RCC1 | MAOA 2254/4885MAOB 2630/4885CYP11B1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.